Tycel Phillips, MD, Oncology, Ann Arbor, MI, Veterans Affairs Ann Arbor Healthcare System

TycelJovellePhillipsMD

Oncology Ann Arbor, MI

Hematologic Oncology

Physician

Dr. Phillips is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Phillips' full profile

Already have an account?

Education & Training

  • Case Western Reserve University - University Hospitals
    Case Western Reserve University - University HospitalsFellowship, Hematology/Oncology, 2009 - 2012
  • John H. Stroger Hospital of Cook County
    John H. Stroger Hospital of Cook CountyResidency, Internal Medicine, 2006 - 2009
  • Rush Medical College
    Rush Medical CollegeClass of 2006

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2012 - 2022
  • OH State Medical License
    OH State Medical License 2009 - 2014
  • IL State Medical License
    IL State Medical License 2006 - 2009
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-HodgkinÍs Lymphoma and C...
    Tycel J. Phillips, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...
    Tycel J. Phillips, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
    Tycel J. Phillips, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Cen... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-) in Patients with Mantle Cell Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Incidence and Clinical Presentation of MCL
    Incidence and Clinical Presentation of MCLFebruary 01, 2020 07:43

Hospital Affiliations